Novel complex therapy of autumnal allergic blepharoconjuctivitis

Abstract

Aim. To assess the effectivity of autumnal allergic blepharoconjuctivitis complex therapy.Methods. 25 autumnal allergic blepharoconjuctivitis patients (50 eyes) were examined before and after complex treatment that included olopatadine hydrochloride 1 mg / ml (instillations 2 times a day), cetirizine 10 mg (1 tablet a day), and steroid drug (insufflations 2 times a day). Dry eye patients additionally received hyaluronic acid 1 mg / ml (instillations 2 times a day). 10 controls (20 eyes) were prescribed only the above-mentioned treatment. In 15 study group patients (30 eyes), Blepharogel 1 was applied on lid margins. Routine eye examination, clinical symptom assessment, Schirmer’s and Norn’s tests, xerosis meter and lissamine green staining evaluation, and anterior segment photography with computed morphometry were performed.Results. Compositae allergy was diagnosed in all patients. Dry eye due to tear film instability, lipid deficiency, and mucin deficiency and epitheliopathy were diagnosed in 55 %, 35.5 % and 28.3 %, respectively. In study group, the treatment significantly and rapidly reduced patient-reported symptoms and blepharoconjunctivitis signs as well as significantly improved tear stability, lipid deficiency, mucin deficiency, and epitheliopathy as compared with controls.Conclusion. Blepharogel 1 as a component of complex therapy increases the efficacy of autumnal allergic blepharoconjuctivitis treatment.

Keywords

• allergy
• blepharoconjunctivitis
• Blepharogel 1.